|Bid||35.13 x 900|
|Ask||35.12 x 1200|
|Day's range||34.35 - 35.52|
|52-week range||27.91 - 41.00|
|Beta (3Y monthly)||0.82|
|PE ratio (TTM)||29.50|
|Earnings date||24 Apr 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||44.35|
We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The U.S. Food and Drug Administration on Tuesday ordered makers of transvaginal surgical mesh implants to immediately stop their sale and distribution in the United States, the latest action by the agency to tackle safety issues related to the devices. The FDA said Boston Scientific Corp and Coloplast A/S did not demonstrate a reasonable assurance of safety and effectiveness of these devices in their premarket applications. The companies will have 10 days to submit their plan to withdraw these products from the market, the FDA said in a statement https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm636114.htm.
The Food and Drug Administration orders Boston Scientific and Coloplast to stop selling surgical mesh used for some pelvic operations.
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The use of Abbott's (ABT) HeartMate 3 pump can efficiently prolong life -term and improve the quality of life for advanced heart failure patients.
Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.
The positive result regarding Boston Scientific's (BSX) LUMINIZE RF Balloon Catheter is expected to help the company further advance with the procedures to clinch a CE Mark for the instrument.
All three major indexes closed in positive territory, despite reports that a meeting between President Donald Trump and Chinese President Xi Jinping may not happen until June. Investors are feeling relatively upbeat as they await news from global central banks this week, including the Federal Reserve on Wednesday. The Dow Jones Industrial Average rose 65.23 points, or 0.3%, to 25,914.1, while the S&P 500 ticked up 10.46 points, or 0.4%, to 2,832.94 and the Nasdaq Composite added 25.95 points, or 0.3%, to 7,714.48.
Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue and EPS growth trajectoryIn its fourth-quarter earnings press release, Boston Scientific (BSX) reported revenues of $9.82 billion for fiscal 2018, a YoY rise of
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Margin guidanceIn the company’s fourth-quarter earnings conference call, Boston Scientific (BSX) has guided for an adjusted gross margin of 72%–73% for fiscal 2018,
Investorideas.com, a leading investor news resource covering medical technology and healthcare stocks releases a snapshot looking at the rapid advancements happening in the med tech sector and how many of these “far off” projects are now on the verge of reality. BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, recently announced that the Company successfully conducted the first patient cases using PURE EP™ System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Expense projections for fiscal 2019 In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted SG&A (selling, general, and
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Earnings projections for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted EPS of $1.53–$1.58 for
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) guided for YoY revenue growth of 7%–9%, YoY organic
How Boston Scientific and Abbott Laboratories Stack UpStock price movementsOn February 15, Boston Scientific (BSX) closed at $40.01, 0.23% higher than its previous closing price, 52.30% higher than its 52-week low of $26.27, and 0.79% below its
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.